Pharma Journalist -

The U.S. Food and Drug Administration approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults. “Emgality provides…
Read More...

SMi Group are delighted to announce that industry expert Digby Harris, Global Category Manager, AstraZeneca will lead a pre-conference workshop on 8th October in London   Workshop…
Read More...

Aldevron announced expansion plans for a 14-acre campus at its headquarters in Fargo, N.D. Phase one construction will begin in August. Upon completion of the campus, the annual…
Read More...

Thermo Fisher Scientific and Newomics will combine their expertise and innovative technologies to develop and optimize sensitive, robust and reproducible microflow LC-MS workflows for…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved Merck’s supplemental New Drug Application (sNDA) for…
Read More...

As the Program Director of the Microbiome Movement, I would like to formally invite you to join us an esteemed member of the delegation for the inaugural Microbiome Movement – Drug…
Read More...

As scientific researchers continue to investigate the complexities of the skin microbiome, our mission for the 2nd Microbiome Movement – Skin Health & Dermatology Summit is simple:…
Read More...

SMi Reports: Registration is now open for the Inaugural Respiratory Drug Delivery conference taking place in London on 13th-14th November 2019. SMi are pleased to announce that…
Read More...

AstraZeneca has presented three-year overall survival (OS) results from the Phase III PACIFIC trial of Imfinzi (durvalumab) in unresectable, Stage III non-small cell lung cancer (NSCLC)…
Read More...

Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), announced that it has entered into a Master Development and Commercialization Agreement with…
Read More...